Veterans with narcolepsy had 64% higher odds of death, a 25-year VA cohort finds
The comparison group matters: against veterans with unspecified narcolepsy diagnoses, the mortality gap widened to 140% higher odds. The study can't yet say what's driving the excess deaths.
Whether narcolepsy itself carries an elevated mortality risk has been, in the words of a study published this month in the Journal of Clinical Sleep Medicine, "highly controversial," with prior research producing inconsistent results and limited comparison against other sleep-clinic populations specifically [s1]. This study uses 25 years of nationwide Veterans Health Administration data to test the question with more statistical power than most prior work.
The design
Researchers used nationwide VA data from October 1999 through March 2025, identifying patients through ICD-9/10 diagnostic codes [s1]. Narcolepsy type 1 (NT1) was defined as having at least two NT1-specific codes; a second "other narcolepsy" (ON) group comprised patients with at least two general narcolepsy codes but no NT1-specific ones [s1]. Two propensity-matched comparison groups were constructed: a General Sleep Clinic (GSC) group with no central-hypersomnia diagnostic codes, matched 1:3 to NT1 patients, and the ON group, matched 1:1 to NT1 patients, both matched on age, sex, race/ethnicity, and diagnosis year [s1]. The final cohort included 4,161 NT1 patients, 4,161 ON patients, and 12,843 GSC patients [s1]. All-cause mortality was the primary outcome, adjusted for age, BMI, and Charlson Comorbidity Index (a measure of overall disease burden) [s1].
What it found
All-cause mortality was more common in both narcolepsy groups than in the general sleep clinic comparison group: 24.7% in NT1, 29.1% in ON, and 15.0% in GSC [s1]. After adjustment, the odds of death were 64% higher in NT1 compared with GSC (adjusted odds ratio 1.64, 95% CI 1.47–1.82) and 140% higher in the ON group compared with GSC (adjusted OR 2.40, 95% CI 2.16–2.66) [s1]. Hospitalization risk was elevated only in the NT1 group specifically (adjusted OR 1.13, 95% CI 1.05–1.22) [s1].
The ON group's higher mortality is the study's most puzzling result
The finding that the "other narcolepsy" group — patients coded for narcolepsy without meeting the more specific NT1 criteria — had a larger mortality gap (140% higher odds) than the more precisely defined NT1 group (64% higher odds) is not what a simple "narcolepsy is dangerous" narrative would predict, and the study's authors don't offer a confident explanation for it. One possibility the design can't rule out: the ON group may be diagnostically heterogeneous, potentially capturing coding for narcolepsy type 2, idiopathic hypersomnia, or diagnostic uncertainty, in ways that could either reflect a genuinely higher-risk population or reflect confounding by whatever other conditions led to imprecise or provisional coding.
What this doesn't establish
This is a retrospective, code-based cohort study using a single health system — the VA — serving a population that skews older, more male, and with distinct comorbidity patterns compared with the general US population, which the study's authors explicitly flag as limiting generalizability beyond VA populations [s1]. Diagnostic codes are an imperfect proxy for confirmed clinical diagnosis, particularly for the less-specific "other narcolepsy" category. The study measures all-cause mortality, not cause-specific mortality — it cannot say what veterans with narcolepsy or other narcolepsy diagnoses were actually dying from, or whether that cause is mechanistically connected to narcolepsy itself versus shared risk factors, comorbidities, or unmeasured confounding that the Charlson Comorbidity Index adjustment doesn't fully capture.
What the authors say is needed next
The study's authors explicitly call for future research to identify cause-specific mortality and modifiable risk factors that could explain and potentially address the excess mortality found here [s1] — an acknowledgment that this cohort establishes an association without yet identifying a mechanism or a point of clinical intervention.
What to watch
Cause-specific mortality analyses within this same VA cohort or similar populations, and whether the pattern replicates outside VA and veteran populations specifically. This article is not medical advice.
Sources
- Mortality in narcolepsy and other sleep clinic patients: a 25-year propensity-matched VA cohort study — Journal of Clinical Sleep Medicine, 4 May 2026
Sources
- Mortality in narcolepsy and other sleep clinic patients: a 25-year propensity-matched VA cohort study — Journal of Clinical Sleep Medicine , May 4, 2026
FDA approves the first drug aimed at the cause of narcolepsy type 1, not just its symptoms
Orzeyful replaces signaling from the brain chemical narcolepsy patients lack, rather than stimulating wakefulness around the gap. Two-thirds of patients on the higher dose had trouble sleeping.
Sleep apnea plus insomnia tripled mortality risk in a six-year cohort of 2,401 patients
Moderate-to-severe sleep apnea alone roughly doubled all-cause mortality risk. Adding comorbid insomnia to the same patients raised it further — evidence for treating the combination as its own risk category.
Tuning daytime and evening light did not improve older adults' sleep
In a 12-person crossover trial, blue-enriched daytime light with reduced evening blue did not cut time spent awake at night, though it nudged a brainwave marker of sleep.
Postpartum depressive symptoms linked to higher infant mortality
In 415,000 New Jersey births, infants of mothers who screened positive for depression died before age one at more than three times the rate, an association steady across race, income and preterm birth.